ScienceDaily
Your source for the latest research news
Follow Facebook Twitter LinkedIn Subscribe RSS Feeds Newsletters
New:
  • Unprecedented Glimpse of Merging Galaxies
  • Chimps Synchronize Their Steps Just Like Humans
  • Secrets of Namibia's Fairy Circles Demystified
  • Black Death Shaped Evolution of Immunity Genes
  • Methane-Eating 'Borgs' Taking Earth's Microbes
  • Pain Relief Without Side Effects and Addiction
  • Accounting For Dark Energy and Dark Matter
  • Meet the First Neanderthal Family
  • Physicists Confirm Hitch in Proton Structure
  • Five Hours' Sleep a Night: Disease Risk
advertisement
Follow all of ScienceDaily's latest research news and top science headlines!
Science News
from research organizations

1

2

B cell receptor inhibitor causes chronic lymphocytic leukemia remission

Date:
December 12, 2011
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, researchers report.
Share:
FULL STORY

A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting of the American Society of Hematology.

advertisement

"PCI-32765, one of a new class of experimental drugs called B cell receptor inhibitors, has shown impressive potential in this clinical trial for its effectiveness and particularly for its relatively minimal toxicity," said lead investigator Susan O'Brien, M.D., professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.

According to the National Cancer Institute's Surveillance Epidemiology and End Results database, an estimated 14,570 people will receive a diagnosis of CLL in 2011 and about 4,380 patients will die of the disease.

Six-month progression free survival of 90-92 percent

Of 27 CLL patients treated at a dose of 420 milligrams daily, 70 percent had complete or partial remission at 10.2 months of median follow-up. Six-month progression-free survival was 92 percent. Patients received a median three prior treatments before entering the clinical trial.

At a higher dose of 840 mg, 44 percent of 34 patients achieved complete or partial remission at 6.5 months median follow-up, similar to the response rate of the lower-dose cohort at 6.2 months. Progression free survival at 6 months was 90 percent. Study participants had received a median of five prior treatments.

advertisement

Overall, five patients (8 percent) of the 61 from both arms had progressive disease and 50 (82 percent) remained on the therapy.

Drug does not suppress blood cell production

CLL presently is treated with combination chemotherapies that can cause myelosuppression -- inhibited bone marrow function leading to decreased production of blood cells. The resulting susceptibility to infection can be a problem for patients, O'Brien said.

"PCI-32765 is not myelosuppressive. The main side effect is mild diarrhea that is usually self-limiting," O'Brien said.

Chronic lymphocytic leukemia is caused by overproduction of defective B cell lymphocytes, white blood cells that fight infection by producing antibodies.

PCI-32765 is orally administered and inhibits the Burton's tyrosine kinas (BT) enzyme, which is central to B cell receptor signaling. The drug causes programmed cell death and hinders cell migration and adhesion in malignant B cells.

A Phase III clinical trial is planned. The clinical trial was funded by Pharmacyclics, Inc., the drug's developer.

Study co-investigators with O'Brien are: Jan Burger, M.D., Ph.D., also of MD Anderson's Department of Leukemia; Kristie Blum, M.D., Amy Johnson, Ph.D., Nyla Heerema, Ph.D., and John Byrd, M.D., of The Ohio State University; Richard Furman, M.D., of Weill Cornell Medical College; Steven Coutre, M.D., of Stanford Cancer Center, Stanford University School of Medicine; Jeff Sharman, M.D., of U.S. Oncology; Ian Flinn, M.D., Ph.D., of Sarah Cannon Research Institute, Nashville, TN; Barbara Grant, M.D., Vermont Cancer Center, University of Vermont, and Tasheda Navarro, Eric Holmgren, Ph.D., and Eric Hedrick, M.D., all of Pharmacyclics, Inc.

make a difference: sponsored opportunity

Story Source:

Materials provided by University of Texas M. D. Anderson Cancer Center. Note: Content may be edited for style and length.


Cite This Page:

  • MLA
  • APA
  • Chicago
University of Texas M. D. Anderson Cancer Center. "B cell receptor inhibitor causes chronic lymphocytic leukemia remission." ScienceDaily. ScienceDaily, 12 December 2011. <www.sciencedaily.com/releases/2011/12/111211134012.htm>.
University of Texas M. D. Anderson Cancer Center. (2011, December 12). B cell receptor inhibitor causes chronic lymphocytic leukemia remission. ScienceDaily. Retrieved October 21, 2022 from www.sciencedaily.com/releases/2011/12/111211134012.htm
University of Texas M. D. Anderson Cancer Center. "B cell receptor inhibitor causes chronic lymphocytic leukemia remission." ScienceDaily. www.sciencedaily.com/releases/2011/12/111211134012.htm (accessed October 21, 2022).

  • RELATED TOPICS
    • Health & Medicine
      • Leukemia
      • Lung Cancer
      • Diseases and Conditions
      • Lymphoma
      • Cancer
      • Colon Cancer
      • Brain Tumor
      • Stem Cells
advertisement

  • RELATED TERMS
    • Psychiatry
    • Sleep disorder
    • Delayed sleep phase syndrome
    • Delirium
    • Functional training
    • Alzheimer's disease
    • Bronchitis
    • Neurology
advertisement

  Print   Email   Share

advertisement

1

2

3

4

5
Most Popular
this week

HEALTH & MEDICINE
Eating Late Increases Hunger, Decreases Calories Burned, and Changes Fat Tissue
Clusters of Genes Help Mice Live Longer
Study of Over 5 Million People's DNA Reveals Genetic Links to Height
MIND & BRAIN
Dogs Can Smell When We're Stressed, Study Suggests
Human Brain Cells in a Dish Learn to Play Pong in Real Time
Healthy Aging Requires an Understanding of Personality Types
LIVING & WELL
Did the Pandemic Change Our Personalities?
Five Hours' Sleep a Night Linked to Higher Risk of Multiple Diseases
Too Much Motivation Affects Our Decision-Making
advertisement

Strange & Offbeat
 

HEALTH & MEDICINE
RNA Origami Enables Applications in Synthetic Biology
Unlocking the Power of Our Emotional Memory
Robotic Drug Capsule Can Deliver Drugs to Gut
MIND & BRAIN
Our Brains Use Quantum Computation
Human Brain Cells in a Dish Learn to Play Pong in Real Time
Dogs Can Smell When We're Stressed, Study Suggests
LIVING & WELL
Researchers Develop Painless Tattoos That Can Be Self-Administered
Washing Dishes With Superheated Steam More Effective, Earth-Friendly
News Addiction Linked to Not Only Poor Mental Wellbeing but Physical Health Too, New Study Shows
Explore More
from ScienceDaily

RELATED STORIES

Investigational Malaria Vaccine Gives Strong, Lasting Protection
June 30, 2021 — Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to ...
CD19 CAR NK-Cell Therapy Achieves 73% Response Rate in Patients With Leukemia and Lymphoma
Feb. 5, 2020 — According to results from a Phase I/IIa trial, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a ...
Drug Combo Heralds Major Shift in Chronic Lymphocytic Leukemia Treatment
July 31, 2019 — A combination of two drugs keeps patients with chronic lymphocytic leukemia disease-free and alive longer than the current standard of care, according to a phase-3 clinical trial of more than 500 ...
New Leukemia Drug Is More Effective and Easier to Use
Jan. 11, 2019 — Oncologists have found that a newer targeted drug is significantly more effective than standard therapy for treating elderly patients with chronic lymphocytic leukemia (CLL). The drug is taken as a ...
advertisement


SD
  • SD
    • Home Page
    • Top Science News
    • Latest News
  • Home
    • Home Page
    • Top Science News
    • Latest News
  • Health
    • View all the latest top news in the health sciences,
      or browse the topics below:
      Health & Medicine
      • Allergy
      • Alternative Medicine
      • Birth Control
      • Cancer
      • Diabetes
      • Diseases
      • Heart Disease
      • HIV and AIDS
      • Obesity
      • Stem Cells
      • ... more topics
      Mind & Brain
      • ADD and ADHD
      • Addiction
      • Alzheimer's
      • Autism
      • Depression
      • Headaches
      • Intelligence
      • Psychology
      • Relationships
      • Schizophrenia
      • ... more topics
      Living Well
      • Parenting
      • Pregnancy
      • Sexual Health
      • Skin Care
      • Men's Health
      • Women's Health
      • Nutrition
      • Diet and Weight Loss
      • Fitness
      • Healthy Aging
      • ... more topics
  • Tech
    • View all the latest top news in the physical sciences & technology,
      or browse the topics below:
      Matter & Energy
      • Aviation
      • Chemistry
      • Electronics
      • Fossil Fuels
      • Nanotechnology
      • Physics
      • Quantum Physics
      • Solar Energy
      • Technology
      • Wind Energy
      • ... more topics
      Space & Time
      • Astronomy
      • Black Holes
      • Dark Matter
      • Extrasolar Planets
      • Mars
      • Moon
      • Solar System
      • Space Telescopes
      • Stars
      • Sun
      • ... more topics
      Computers & Math
      • Artificial Intelligence
      • Communications
      • Computer Science
      • Hacking
      • Mathematics
      • Quantum Computers
      • Robotics
      • Software
      • Video Games
      • Virtual Reality
      • ... more topics
  • Enviro
    • View all the latest top news in the environmental sciences,
      or browse the topics below:
      Plants & Animals
      • Agriculture and Food
      • Animals
      • Biology
      • Biotechnology
      • Endangered Animals
      • Extinction
      • Genetically Modified
      • Microbes and More
      • New Species
      • Zoology
      • ... more topics
      Earth & Climate
      • Climate
      • Earthquakes
      • Environment
      • Geography
      • Geology
      • Global Warming
      • Hurricanes
      • Ozone Holes
      • Pollution
      • Weather
      • ... more topics
      Fossils & Ruins
      • Ancient Civilizations
      • Anthropology
      • Archaeology
      • Dinosaurs
      • Early Humans
      • Early Mammals
      • Evolution
      • Lost Treasures
      • Origin of Life
      • Paleontology
      • ... more topics
  • Society
    • View all the latest top news in the social sciences & education,
      or browse the topics below:
      Science & Society
      • Arts & Culture
      • Consumerism
      • Economics
      • Political Science
      • Privacy Issues
      • Public Health
      • Racial Disparity
      • Religion
      • Sports
      • World Development
      • ... more topics
      Business & Industry
      • Biotechnology & Bioengineering
      • Computers & Internet
      • Energy & Resources
      • Engineering
      • Medical Technology
      • Pharmaceuticals
      • Transportation
      • ... more topics
      Education & Learning
      • Animal Learning & Intelligence
      • Creativity
      • Educational Psychology
      • Educational Technology
      • Infant & Preschool Learning
      • Learning Disorders
      • STEM Education
      • ... more topics
  • Quirky
    • Top News
    • Human Quirks
    • Odd Creatures
    • Bizarre Things
    • Weird World
Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

  • Email Newsletters
  • RSS Feeds
Follow Us

Keep up to date with the latest news from ScienceDaily via social networks:

  • Facebook
  • Twitter
  • LinkedIn
Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

  • Leave Feedback
  • Contact Us
About This Site  |  Staff  |  Reviews  |  Contribute  |  Advertise  |  Privacy Policy  |  Editorial Policy  |  Terms of Use
Copyright 1995-2022 ScienceDaily or by other parties, where indicated. All rights controlled by their respective owners.
Content on this website is for information only. It is not intended to provide medical or other professional advice.
Views expressed here do not necessarily reflect those of ScienceDaily, its staff, its contributors, or its partners.
Financial support for ScienceDaily comes from advertisements and referral programs, where indicated.
— CCPA: Do Not Sell My Information — GDPR: Privacy Settings —